SNAIL is a key regulator of alveolar rhabdomyosarcoma tumor growth and differentiation through repression of MYF5 and MYOD function

Klaudia Skrzypek1, Anna Kusienicka1, Elzbieta Trzyna1, Barbara Szewczyk1, Aleksandra Ulman1, Pawel Konieczny1, Tomasz Adamus1, Boga Badyra1, Marcin Kortylewski2 and Marcin Majka1

Abstract

Rhabdomyosarcoma (RMS) is a mesenchymal tumor of soft tissue in children that originates from a myogenic differentiation defect. Expression of SNAIL transcription factor is elevated in the alveolar subtype of RMS (ARMS), characterized by a low myogenic differentiation status and high aggressiveness. In RMS patients SNAIL level increases with higher stage. Moreover, SNAIL level negatively correlates with MYF5 expression. The differentiation of human ARMS cells diminishes SNAIL level. SNAIL silencing in ARMS cells inhibits proliferation and induces differentiation \textit{in vitro}, and thereby completely abolishes the growth of human ARMS xenotransplants \textit{in vivo}. SNAIL silencing induces myogenic differentiation by upregulation of myogenic factors and muscle-specific microRNAs, such as miR-206. SNAIL binds to the MYF5 promoter suppressing its expression. SNAIL displaces MYOD from E-box sequences (CANNTG) that are associated with genes expressed during differentiation and G/C rich in their central dinucleotides. SNAIL silencing allows the re-expression of MYF5 and canonical MYOD binding, promoting ARMS cell myogenic differentiation. In differentiating ARMS cells SNAIL forms repressive complex with histone deacetylases 1 and 2 (HDAC1/2) and regulates their expression. Accordingly, in human myoblasts SNAIL silencing induces differentiation by upregulation of myogenic factors. Our data clearly point to SNAIL as a key regulator of myogenic differentiation and a new promising target for future ARMS therapies.

Introduction

Rhabdomyosarcoma (RMS) is the most frequently occurring soft tissue sarcoma among children and adolescents, however, rare instances of the disease have been noted in adults. Based on histological analysis of the tumor, two major RMS subtypes may be distinguished: embryonal (ERMS) and alveolar (ARMS). ERMS is usually associated with better survival and typically occurs in the head and neck and urogenital tract. ARMS occurs in the extremities and trunk and generally has a significantly worse prognosis\textsuperscript{1–3}. High aggressiveness of ARMS subtype is associated with presence of PAX3-FOXO1 or PAX7-FOXO1 fusion genes and increased levels of MET receptor, a member of tyrosine kinase receptors family (RTK), which is associated with metastatic potential of RMS cells\textsuperscript{2,4}. RMS development is likely connected to a differentiation defect of stem cells or early progenitors, such as mesenchymal stem cells or satellite cells/myoblasts\textsuperscript{3,5,6}.

Myogenic differentiation is regulated by different early and late myogenic factors. These basic helix-loop-helix (bHLH) transcription activators contain a conserved DNA
binding domain, that recognizes the enhancer box (E-box) motif. Myogenic factor 5 (MYF5) and myogenic differentiation 1 (MYOD/MYOD1) are responsible for the early stages of differentiation, whereas myogenin (MYOG) and myogenic factor 6 (MRF4) are responsible for terminal differentiation. Those myogenic factors regulate genes and muscle-specific microRNAs. An interesting example is miR-206, which is induced by MYOD to enhance differentiation and facilitate cell cycle exit. Aberrations within the regulatory myogenic pathway described above may be one of the crucial causes of the rhabdomyosarcoma development.

In our previous work, we observed that aggressive ARMS tumors display higher expression of the SNAIL gene and that SNAIL expression positively correlates with PAX3/7-FOXO1. SNAIL (snail family zinc finger 1; SNAI1) is a member of the group of zinc finger transcription factors. The SNAIL family consists of 3 members: SNAIL (SNAI1), SLUG (SNAI2) and SMUG (SNAI3). SNAIL plays an eminent role in the epithelial to mesenchymal transition (EMT), the main mechanism responsible for both embryogenesis and the invasiveness and metastasis of neoplasms. By binding to target E-box sequences (CANNTG), SNAIL acts as a transcriptional repressor, but it may also work as a gene activator. SNAIL causes epigenetic changes in chromatin structure, mainly by recruiting histone deacetylases (HDACs).

The role of SNAIL in non-epithelial tumors is poorly understood. Recent data have provided evidence that SNAIL plays an important role in cells of mesenchymal origin. Murine fibroblasts expressing SNAIL in epithelial tumor microenvironment support metastasis, given their mechanical properties. Moreover, when SNAIL expression is reactivated in mesenchymal cells, they may become invasive, whereas SNAIL-deficient fibroblasts do not display invasive capabilities. Activated mesenchymal cells display SNAIL expression, and SNAIL seems to play an important role in the communication between the stroma and the tumor and it can facilitate the conversion of cancer cells to stromal cells. In sarcomas and fibrosarcomas, SNAIL levels are elevated. However, the precise mechanism of its action remains unknown.

The mechanistic role of SNAIL in the biology of ARMS has not been investigated, although, the important role of SNAIL in murine myogenesis has been described previously. SNAIL zinc-finger binding domains recognize the same E-box sequence as bHLH myogenic transcription factors. The repressive complex of SNAIL with HDACs binds and excludes MYOD from G/C-rich E-box motifs in murine satellite cells, thereby inhibiting myogenic differentiation. In RMS SNAIL expression is higher in ARMS tumor that is associated with worse prognosis and SNAIL is a mediator of NOTCH pathway in ERMS subtype.

Here, we demonstrate for the first time that SNAIL blocks human ARMS differentiation and promotes tumor development. Importantly, our study describes the molecular mechanism of SNAIL, which deregulates growth and myogenic differentiation of ARMS cells through interference with the early myogenic transcription factors, MYF5 and MYOD.

**Results**

**SNAIL expression is associated with RMS myogenic differentiation**

Because RMS can originate from the impaired differentiation of myogenic progenitors, we analyzed the expression of myogenic regulatory factors and SNAIL in patient samples obtained from two major RMS subtypes, ERMS and ARMS. Bioinformatical analysis of microarray data deposited in GEO database (ref. 20) was performed according to literature and revealed that in 158 RMS patients samples SNAIL level negatively correlated with MYF5 level (Fig. 1a) and positively correlated with MYOD (Fig. 1b). In a group of 158 samples SNAIL level turned out to be significantly increased in RMS samples from patients displaying the stages of the disease 2, 3, and 4 compared to stage 1, what suggested an important role of SNAIL in RMS progression (Fig. 1c). Moreover, SNAIL level was elevated in ARMS compared to ERMS (Fig. 1d), what is in accordance with the staging results, because ARMS is not included in stage 1 due to more unfavorable histology. Those data indicated that SNAIL may play an important role in the development of less differentiated ARMS tumors that are associated with worse prognosis.

SNAIL levels were also significantly increased in RH41 and RH30 ARMS cell lines compared with RD and RH18 ERMS cell lines, and the levels were comparable with the SNAIL level in human myoblasts at early passages, whereas differentiated myotubes displayed the diminished SNAIL levels that were comparable with ERMS cells (Fig. 1e). Forced myogenic differentiation of RH30 ARMS cells for 7 days significantly diminished SNAIL expression at the mRNA and protein levels (Fig. 1f). These results suggested the direct association of SNAIL expression with myogenic differentiation.

**SNAIL silencing changes the ARMS phenotype and completely inhibits tumor growth in mice**

Since ARMS tumors and cell lines display increased SNAIL levels, we silenced SNAIL with siRNA in RH41 and RH30 ARMS cells and treated the cells with differentiating medium for the next 2 days. Transient SNAIL silencing diminished the cell proliferation and induced the acquisition of a more elongated (spindle-shaped) phenotype (Fig. 2a). Moreover, two different siRNA sequences against SNAIL resulted in acquisition of the elongated phenotype (spindle shape) in RH30 and RH41 cells.
SNAIL expression is associated with RMS subtype and myogenic differentiation. 

**a** Expression of early and late myogenic factors in 158 RMS samples was estimated previously by microarray and deposited in GEO database with accession number: GSE92689 (ref.20). SNAIL level negatively correlates with MYF5 level in RMS (Pearson correlation). 

**b** SNAIL level positively correlates with MYOD level in RMS (Pearson correlation). 

**c** Increased SNAIL levels in RMS stage 2,3 and 4 compared to 1 were demonstrated in a group of 158 RMS samples (microarray data, GEO database GSE92689). The data are presented as Whisker plots min to max. 

**d** Increased SNAIL level in ARMS compared to ERMS was demonstrated in a group of 158 RMS samples (microarray data, GEO database GSE92689). The data are presented as Whisker plots min to max. 

**e** SNAIL expression was quantified by qPCR using the ΔCt quantification method and GAPDH as a housekeeping gene control in ARMS and ERMS cell lines and human primary myoblasts. The SNAIL level is increased in RH30 and RH41 ARMS cell lines compared to RD and RH18 ERMS cell lines, and the level is comparable with the SNAIL level in myoblasts at the early passage (undiff.), whereas in the differentiated myotubes (diff.) SNAIL level is more comparable with ERMS. n = 3. 

**f** Differentiation of RH30 cells by culture in medium supplemented with 2% HS for 7 days downregulates SNAIL expression at the mRNA level (qPCR) and protein level (Western blotting); n = 4. The data represent the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
SNAIL silencing in ARMS directly upregulates MYF5 and excludes MYOD from its DNA binding sites

Since expression of SNAIL negatively correlated with expression of myogenic factors, we hypothesized that complete inhibition of tumor growth in vivo may be a result of the myogenic differentiation of the cells. To evaluate this hypothesis, we investigated the effect of SNAIL on different early and late myogenic factors. SNAIL did not exert the significant effect on MYOD expression (Fig. 4a). Interestingly, the nuclei of RH30 shSNAIL cells displayed strong MYF5 expression, whereas control cells did not express MYF5 what was confirmed by Western blot analysis (Fig. 4b). Similarly, MYF5 mRNA was not expressed in RH30 cells, but SNAIL silencing strongly induced its expression in both undifferentiated and differentiated cells (Fig. 4c).

Accordingly, we stably silenced SNAIL level in RH41 cells by transduction of RH41 cells with shRNA vectors (shSNAIL cells) and protein downregulation was verified (Supplementary Figure 2a). In those cells MYF5 expression was also induced (Fig. 4d). Moreover, temporal silencing of SNAIL expression for three days was sufficient for the induction of MYF5 expression in different ARMS cell lines: RH30 and RH41 (Fig. 4e). Interestingly, transfection of RH30 cells with the miR-30a precursor, a known negative regulator of SNAIL protein expression, resulted in the downregulation of SNAIL and the upregulation of MYF5 levels (Fig. 4f). Thus, our data suggest that SNAIL is a crucial regulator of MYF5 expression in ARMS.

In murine myoblasts, the Snail-Hdac1/2 repressive complex binds and excludes MyoD from its targets, thus preventing MyoD occupancy on differentiation-specific regulatory elements. Thus, we hypothesized that in human ARMS SNAIL may also compete with MYOD for binding to G/C rich E-Box sequences. Indeed, SNAIL silencing in RH30 cells resulted in increased MYOD binding to G/C rich E-box sequences. This resulted in activation of MYF5 promoter in a same way that it binds to E-cadherin promoter (Fig. 5a, Fig. 5b, 5c). Interestingly, the therapy resulted in appearance of differentiated morphology of tumors treated with SNAIL siRNA (Fig. 3f) and those regions displayed diminished SNAIL expression (Fig. 3g).
Fig. 2 (See legend on next page.)
promoter, whereas MYOD silencing repressed it. Moreover, silencing of both MYOD and SNAIL reversed the effects (Fig. 5d–f). Those results suggested that there is a competition between SNAIL and MYOD for binding to G/C rich E-boxes in MYF5 promoter.

**SNAIL regulates expression of HDAC1/2 and forms complexes with them in ARMS**

HDAC1 and HDAC2 are the components of the repressive SNAIL complex known from the literature14. HDAC1 was strongly and HDAC2 was slightly downregulated in differentiated RH30 shSNAIL cells both at mRNA (Fig. 6a) and at protein level (Fig. 6b). To confirm that the observed effects are SNAIL dependent, we transduced RH30 shSNAIL with lentiviral vectors encoding GFP-P2A-SNAIL, and a scrambled siRNA sequence (siRNA). 24 h after transfection medium was changed for a differentiating medium containing 2% HS for the next 2 days. SNAIL silencing with siRNA for 3 days was validated by qPCR, n = 4. The morphology of the cells was visualized with Wright’s staining (error bar represent 100 μm). Proliferation was evaluated by MTS assay; n = 3. b To stably silence the SNAIL level, RH30 cells were transduced with shRNA lentiviral vectors targeting SNAIL (shSNAIL) and control vectors (shCTRL), and these cells were selected with puromycin. SNAIL silencing was validated by qPCR (n = 3) and Western blotting (total cell extracts). c Stable SNAIL silencing in RH30 cells leads to the acquisition of a spindle- shaped phenotype and reorganization of the cytoskeleton. The morphology of RH30 cells differentiated for 4 days was visualized with Wright’s staining and for 6 days with phase contrast microscopy. d SNAIL silencing and the differentiation of RH30 cells led to cell cycle arrest at the G0-G1 phase and diminished percentage of the cells in S phase. RH30 cells were differentiated for 7 days in medium containing 2% HS. Subsequently, the cell cycle and BrdU incorporation in S phase were analyzed by flow cytometry—the cells were stained with anti-BrdU antibody conjugated with APC and with 7AAD. The data in the graphs represent the mean ± SEM or are representative images of at least 3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001

**SNAIL silencing in ARMS induces expression of myogenic factors and muscle-specific microRNAs**

SNAIL silencing by shRNA in RH30 cells also increased the expression of other myogenic factors, including MYOD dependent or independent ones, such as MEF2A (myocyte enhancer factor 2A), myogenin, myostatin, MyHC (myosin heavy chain) at mRNA level (Fig. 7a). Moreover, our study revealed an increased expression of myogenin (Fig. 7a) and MyHC (Fig. 7b) at protein levels in RH30 shSNAIL cells. SNAIL downregulation resulted in appearance of the elongated cells with high MyHC level with more than one nuclei resembling myotubes and induced fusion of the cells (Fig. 7b). Muscle-specific microRNAs, such as miR-1, miR-133b, miR-378a-3p, and miR-206 were also upregulated in RH30 shSNAIL cells (Fig. 7c). To verify if miR-206 is a mediator of SNAIL action on MyHC level, RH30 WT cells were transfected with miR-206 precursor (pre-miR-206) and RH30 shSNAIL cells were transfected with miR-206 inhibitor (anti-miR-206). Transfection of RH30 WT cells with the miR-206 precursor increased MyHC levels, whereas inhibition of miR-206 with anti-miR sequences in RH30 shSNAIL cells partially reversed the effect of SNAIL on MyHC (Fig. 7d). Those results indicated that miR-206 is a mediator of SNAIL action on MyHC level.

By transfection with CRISPR/Cas9 nucleases targeting SNAIL we developed two ARMS cell lines—RH41 and RH30 with SNAIL knockout (Supplementary Figure 2b and 2c). By homologous directed repair of the site-specific Cas9-induced double strand break within SNAIL gene puromycin resistance gene and red fluorescent protein (RFP) were incorporated into that locus. Cells were selected in puromycin and subsequently sorted for the brightest ones, what resulted in around 95% of the cells positive for RFP (Supplementary Figure 2d and e). Nevertheless, after 4 weeks of culture only 75% of the RH41 cells were positive for RFP and after 6 weeks of culture the population diminished to 60% (Supplementary Figure 2f). Similarly, after 4 weeks of culture the population of RFP positive RH30 cells diminished from 95 to 4% and almost disappeared after 6 weeks (Supplementary Figure 2g). Those results from RH30 and RH41 cells suggested that SNAIL knockout on both alleles may be a lethal mutation and those cells are not able to survive in vitro. Previously, we observed lethality of RH30 cells with diminished SNAIL level after shRNA in vivo.

When we characterized those cell lines we observed that differentiating RH41 SNAIL deficient cells acquired spindle-shaped morphology (Supplementary Figure 2h). RH30 CRISPR cells became elongated even in standard culture conditions (Supplementary Figure 2). An
Fig. 3 (See legend on next page.)
increased expression of myogenic factors, such as MEF2A, myogenin, myostatin and MyHC was also observed (Supplementary Figure 2i and 2b).

These data suggest that we discovered a novel non-canonical mechanism of SNAIL action, which may be of significance in the regulation of human physiological and pathological myogenesis. Interestingly, when human primary myoblasts were cultured for several passages, what led to their differentiation, the SNAIL level decreased (Fig. 8a). Accordingly, the transient downregulation of SNAIL levels by transfection with siRNA resulted in the increased myoblasts differentiation and upregulation of early and late differentiation factors, such as MYF5, MRF4, myogenin and MyHC at mRNA or protein level (Fig. 8b, c), suggesting that SNAIL plays a crucial role in the regulation of myogenic differentiation. Indeed, SNAIL silencing increased fusion of the cells and appearance of multinucleated myotubes (Fig. 8d).

These results indicate for the first time that muscle-specific miRNAs and myogenic regulatory factors are important mediators of SNAIL anti-myogenic action in ARMS (Fig. 8e).

Discussion
This study was undertaken to investigate the novel role of the SNAIL transcription factor in the regulation of ARMS growth and myogenic differentiation. SNAIL is known as a master regulator of the growth and metastasis of epithelial tumors, and its canonical action involves the induction of the EMT. Interestingly, the role of SNAIL in the biology of mesenchymal tumors is poorly understood. Here, we showed that SNAIL regulates differentiation of ARMS cells. This is exerted through regulation of myogenic factors and microRNAs. We revealed the novel mechanism of the anti-myogenic action of human SNAIL, a function that may be relevant not only in RMS but also in other physiological processes.

In our studies, we demonstrated for the first time that SNAIL is a crucial negative regulator of myogenic differentiation in ARMS through disruption of early myogenic transcription factors functions; therefore, SNAIL may be a novel target for future therapies. We demonstrated also that SNAIL is crucial for the differentiation of human primary myoblasts. Our results are supported by the recent papers demonstrating that, Snail regulates the differentiation of murine myoblasts. Inhibition of Snail leads to the induction of myogenic differentiation of these cells, whereas its upregulation inhibits C2C12 myotube differentiation. Additionally, a recent study demonstrated that murine Snail also controls cardiomyocyte development in embryogenesis and that its expression is important in mesodermal commitment and differentiation.

RMS cells display expression of several myogenic factors, but they do not complete normal myogenic differentiation. We suggest that SNAIL may be a crucial factor responsible for the dysregulation of myogenic differentiation, leading to ARMS development. Because ERMS may be derived from impaired differentiation of MSCs, in our previous studies we demonstrated that the constitutive activation of MET receptor signaling in MSCs may lead to their myogenic differentiation probably by regulation of SNAIL expression. In the current study, we describe the novel mechanism of SNAIL action in ARMS and demonstrate that SNAIL regulates two important early myogenic factors in RMS.

SNAIL decreases MYOD binding to G/C-rich E-boxes, with possible implications for the physiological myogenesis. Early efforts to investigate the phenomenon of the impaired differentiation of RMS focused on MYOD. Previous papers have suggested that RMS cells express MYOD, but it appears to be nonfunctional as a transcriptional coactivator. Based on our data, SNAIL appears to be a novel factor that regulates MYOD transcriptional activity, a finding that has been lacking.
Fig. 4 (See legend on next page.)
previously. In murine myoblasts, inhibition of the Snail complex with Hdac1/2 leads to the induction of myogenic differentiation by competition with MyoD for binding to E-box sequences. Our studies suggest that a similar mechanism of action is also crucial for the myogenic differentiation of human RMS cells. SNAIL mediates the repression of different gene promoters by recruitment of the HDAC1/HDAC2 complex. We showed that in differentiating ARMS cells, SNAIL recruits and regulates the expression of HDAC1 and HDAC2.

Importantly, in RMS, the SNAIL transcription factor is an important regulator of the MYOD-miR-206-MyHC axis, thereby regulating myogenic differentiation. MYOD induces the expression of numerous myogenic genes, such as desmin, MEF2A and myogenin, that are regulated by Snail and Slug in murine myoblasts. One of the downstream mediators of MYOD is miR-206 (ref. 10), which induces the late myogenic differentiation of RMS cells and the expression of myosin heavy chain (MyHC). miR-206 inhibits RMS growth by the induction of differentiation32, and miR-206 induces the expression of MyHC-positive differentiating myoblasts.

Both MYF5 and MYOD were demonstrated to be important transcriptional targets regulating human RMS growth. In early development both factors are required for the formation of skeletal myoblasts, and mutant mice without both factors do not develop skeletal muscles. Muscle progenitors with MYOD expression but lacking MYF5 expression may either remain highly proliferative and developmentally arrested or differentiate into mesenchymal progeny, suggesting that MYOD is a crucial regulator of the proliferation to differentiation switch. Determination of the myogenic fate of stem cells requires the progressive expression of MYF5, MYOD, and subsequently myogenin (MYOG) and myofibrillar proteins, such as the myosin heavy chain. Progenitors expressing MYF5 and MYOD can divide several times before terminal differentiation. Accordingly, RH30 ARMS cells with silenced SNAIL are MYF5 and MYOD positive. These cells divide in vitro but do not form any tumors in vivo.

Importantly, our data demonstrated that SNAIL negatively regulates MYF5 expression in ARMS. These data are consistent with those of previous studies indicating that MYF5 expression is increased in ERMS cells compared with more proliferative ARMS cells. Those studies also suggested that MYF5 is a novel RMS class predictor. Additionally, ERMS cells positive for MYF5 do not display pro-invasive capabilities, but they play supportive roles in tumor progression. Accordingly, PAX3/FOXO1 translocation-positive ARMS cells do not display MYF5 expression. In this study through SNAIL silencing we demonstrated for the first time that SNAIL is the main inhibitor of MYF5 expression in ARMS displaying PAX3-FOXO1 translocation. PAX3-FOXO1 translocation is present in RH30 and RH41 cells, and it cannot be excluded that PAX3-FOXO1 may act upstream of SNAIL in the regulation of MYF5 expression. In mice, Myf5 gene contains a large regulatory region 145 kb 5’ upstream of the transcription start site. Numerous regulatory transcription factors can bind to this region, including Pax3, which binds to the −58/−56 kb distal Myf5 enhancer. Accordingly, in RMS, PAX3-FOXO1 also binds to a similar region. Importantly, PAX3 is an upstream regulator of SNAIL and Slug in embryonic development. Therefore, in the future, the effect of PAX3-FOXO1 on SNAIL activity should also be investigated, as SNAIL level may be elevated in ARMS compared to ERMS due to PAX3-FOXO1 expression in ARMS.

Interestingly, approximately 10% of satellite cells in quiescent muscles never express MYF5. These cells display self-renewal potential, suggesting that the induction of MYF5 expression induces subsequent differentiation steps. The regulation of the MYF5 level appears to be crucial in ARMS growth, and MYF5 may be one of the most important mediators of SNAIL action. We demonstrated a novel mechanism for SNAIL: it binds directly to the MYF5 promoter and inhibits its expression.
Fig. 5 (See legend on next page.)
in ARMS tumors, thereby regulating myogenic differentiation. Surprisingly, in chick embryos SNAIL was demonstrated to be a necessary and sufficient step for the NOTCH-dependent activation of MYF5 in the medial border of the dermomyotome, which suggests either its opposite role in different species or in normal myogenesis.

In conclusion, the induction of ARMS differentiation by SNAIL silencing leads to the complete inhibition of tumor growth, suggesting that SNAIL may be a novel target for differentiation-based therapies in human ARMS. The mechanism of SNAIL action on MYF5 expression and MYOD activity may also be of significance for further studies on myogenesis during embryonic development.

**Materials and methods**

**Cell culture**

RMS cell lines (RH30, RH41, RD) were kindly provided by Dr. PJ Houghton (Center for Childhood Cancer, Columbus, OH, USA) or ordered from the American Type Culture Collection (ATCC, Manassas, VA, USA). RH18 ERMS cell line was ordered from DSMZ (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures in Germany). The cells were cultured in DMEM high-glucose medium (Lonza Group Ltd., Basel, Switzerland) supplemented with 10% fetal bovine serum (FBS, EURx, Gdansk, Poland) and 50 μg/ml gentamicin (Lonza) at 37 °C, 5% CO2 and 95% humidity. The RMS cell lines were differentiated in DMEM low-glucose medium (Lonza) supplemented with 2% horse serum (Lonza) at 37 °C, 5% CO2 and 95% humidity. Shorter incubation periods resulted in strong elongation of the cells (acquisition of spindle shape). The cellular morphology was visualized using Wright’s stain (Sigma-Aldrich, St. Louis, MO, USA).

The cell lines were routinely tested for Mycoplasma contamination using MycoAlert™ Mycoplasma Detection Kit (Lonza). Cell line authentication was performed by STR profiling using AmpFISTR SGM PLUS Kit (Applied Biosystems, Foster City, CA, USA) and sequencing apparatus ABI Prism 310 Genetic Analyser (Applied Biosystems) according to the manufacturer’s protocol.

Primary human myoblasts were isolated by our lab and characterized as previously described. These cells were cultured in DMEM/F12 medium (Lonza) supplemented with dexamethasone, insulin (both from Sigma-Aldrich) 18% FBS (EURx), EGF (R&D Systems, Minneapolis, MN, USA), FGF (R&D), HGF (R&D) and gentamicin (Lonza). They were differentiated in DMEM low-glucose medium (Lonza) supplemented with 2% horse serum (HS) (Gibco).

**Production of viral vectors and transduction of cells**

RH30 and RH41 cells were transduced with shRNA Lentiviral Particles targeting SNAIL and control lentiviral particles at an MOI of 2.5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-38398-V and sc-108080) in 6 μg/ml polybrene (Sigma, St. Louis, MO, USA) according to the manufacturer’s protocol. SNAIL shRNA lentiviral particles are a pool of concentrated, transduction-ready viral particles containing 3 different target–specific constructs that encode 19–25 nt (plus hairpin) shRNA designed to knock down SNAIL. Transduced cells were selected with 0.5 μg/ml puromycin (InvivoGen, San Diego, CA, USA). Lentiviral particles encoding GFP–P2A–SNAIL (GFP–P2A–SNAIL @pLent6/VbC) were produced using the Vira Power Lentiviral Expression System (Invitrogen, Carlsbad, CA, USA), as previously described. RH30 shSNAIL cells were transduced with GFP–P2A–SNAIL lentiviral vectors at an MOI of 10 in the presence of 6 μg/ml polybrene (Sigma-Aldrich). After 72 h the cells were subject to selection with 5 μg/ml blasticidin (InvivoGen) for 2 weeks.

**Transfection with siRNA**

RH30, RH41 cells and human myoblasts were transfected with 20 nM siRNA against SNAIL (combination of two Silencer Select siRNA ID variants: s13185 and s13187, Ambion Inc., Austin, TX, USA) or scrambled control.
siRNA (Silencer Select Negative Control #1 siRNA, cat. 4390844, Ambion) using Lipofectamine 2000 (Invitrogen) or Lipofectamine RNAiMAX transfection reagent according to vendor’s instructions. Twenty-four hours later, the transduction medium was changed to differentiating medium supplemented with 2% HS. RNA or protein was isolated 72 h after transfection. The cellular morphology was visualized using Wright’s stain (Sigma-Aldrich). Proliferation of RH30 and RH41 cells transfected on 96-well plates with siRNA was estimated using CellTiter 96® AQueous One Solution assay (Promega, WI, USA), according to vendor’s protocol.

Transfection of cells with miRNA precursors and inhibitors
RH30 cells were transfected with 30 nM pre-miR-30a-5p (ID: PM11062, Ambion) or 30 nM pre-miR-206 (ID: PM10409, Ambion) miRNA precursors and pre-miR negative controls (ID: AM17110, Ambion) or

---

**Fig. 6 SNAIL regulates expression of HDAC1/2 and form complexes with them in ARMS.**

- **a** HDAC1 and HDAC2 mRNA (qPCR, expression relative to GAPDH, n = 3) and protein (**b**) (Western blot) expression is inhibited in RH30 cells differentiated for 7 days in medium with 2% HS. **c** Transduction of RH30 shSNAIL with lentiviral vectors encoding SNAIL reverses the effect of SNAIL silencing on SNAIL, HDAC1, and HDAC2 protein levels, what was additionally confirmed by densitometric analysis (n = 2). **d** SNAIL form complexes with HDAC1, HDAC2 and histone H3. Co-IP of SNAIL and HDAC1, HDAC2, MYOD, histone H3 was performed. No antibody added in IP served as a negative control (neg-ctrl), whereas the input protein extract served as a positive control. The data represent the mean ± SEM or are representative images of at least 3 independent experiments. *p < 0.05
Fig. 7 (See legend on next page.)
alternatively with 30 nM anti-miR miRNA inhibitors against miR-206 (ID: AM10409, Ambion) and negative controls (ID: AM17010, Ambion) using the siPORT NeoFX transfection reagent (Ambion) according to the manufacturer’s instructions, as described previously.41

Twenty-four hours later, the transduction medium was changed to differentiating medium supplemented with 2% HS. RNA was isolated 72 h after transfection.

Generation of SNAIL CRISPR knockout

8 x 10^4 RH30 and RH41 cells were seeded per one well of a 24-well plate. The next day the cells were transfected with 500 ng of SNAIL CRISPR/Cas9 KO plasmid (Santa Cruz Biotechnology, sc-400244) and 500 ng of SNAIL HDR plasmid (Santa Cruz Biotechnology, sc-400244-HDR) using Lipofectamine 2000 (Invitrogen) according to vendor’s instructions. SNAIL CRISPR/Cas9 KO plasmid consists of a pool of 3 plasmids, each encoding the Cas9 nuclease and a target-specific 20 nt guide RNA designed for maximum knockout efficiency. SNAIL HDR plasmid consists of a pool of 2–3 plasmids, each containing a homology directed DNA repair (HDR) templates corresponding to the cut sites generated by the SNAIL CRISPR/Cas9 KO plasmid. Each HDR template contains two 800 bp homology arms designed to specifically bind to the genomic DNA surrounding the corresponding Cas9-induced double strand DNA break site. During the repair, the SNAIL HDR plasmid incorporates a purumycin resistance gene and red fluorescence gene (RFP).

Seventy-two hours after transfection, the RH30 and RH41 cells were selected with 0.5 μg/mL puromycin (InvivoGen, San Diego, CA, USA) for 2 weeks and subsequently they were sorted to select the cells with the brightest expression of RFP using BD FACSaria (BD Biosciences). Successful co-transfection of the CRISPR/Cas9 KO Plasmid and HDR Plasmid was visually confirmed by detection of RFP via fluorescent microscopy and using Attune flow cytometer (ThermoFisher Scientific). Around 95% of the cells were positive for RFP after the sorting.

Bioinformatical analysis of microarray data from RMS patients

For gene expression analysis in a group of 158 RMS patients we used data from GEO database, stored under accession number GSE92689 (ref. 20). Background subtraction and data normalization was performed with affy package[21] in R/Bioconductor and the average expression was used for further statistical analysis. Pearson correlation of gene expression was analyzed using GraphPad Prism software. Statistical analysis of SNAIL expression in RMS stages and RMS subtypes was performed by Mann–Whitney test using GraphPad Prism software.

DNA and RNA isolation and reverse transcription

Total RNA was extracted using the Universal RNA purification kit (EURx), according to the manufacturer’s protocol. For the analysis of both miRNA and mRNA expression, total RNA was isolated using the mirVana miRNA Isolation Kit (Ambion). Reverse transcription of mRNA was performed using MMLV reverse transcriptase (Promega, Madison, WI, USA) according to the manufacturer’s protocol. Reverse transcription of both miRNA and mRNA was performed using the NCode VILO miRNA cDNA Synthesis Kit (Invitrogen), according to the manufacturer’s protocol.

Quantitative real-time PCR

Gene expression was determined by qRT-PCR analysis using ABI PRISM 7300 Sequence Detection System or Quant Studio 7 Flex System (both from Applied Biosystems, Foster City, CA, USA), Blank qPCR Master Mix (EURx) and the indicated Taq-Man probes (Applied Biosystems): human: GAPDH (Hs99999905_s1), MYF5 (Hs00271574_m1), MYOD (Hs00159528_m1), MRF4
Fig. 8 (See legend on next page.)
Fig. 8 SNAIL silencing in human myoblasts increases expression of myogenic factors. a SNAIL expression in human myoblasts diminishes with subsequent passages (qPCR, n = 4). b Human myoblasts were transfected with siRNA against SNAIL (siSNAIL) and with a scrambled siRNA sequence (siRNA) or they were treated with transfection reagent (mock). 24 h after transfection they were treated with a differentiating medium containing 2% HS for the next 48 h. SNAIL silencing was validated by Western blot. SNAIL silencing increased the myogenin and MyHC protein levels (Western blot). c Expression of SNAIL, MYF5, MYOD, MRF4, myogenin and MyHC was determined by qPCR with ΔCt quantification method and GAPDH as a housekeeping gene control. SNAIL silencing and differentiation induces expression of the analyzed myogenic factors. d SNAIL silencing increases the number of the myotubes with high MyHC expression and induces their fusion. The images are representative merged images of immunofluorescent staining for MyHC (red; nuclei: Hoechst, blue) of myotubes. The scale bar represents 100 μm. Fusion index was calculated by expressing the number of nuclei within MyHC-positive myotubes with ≥2 nuclei as a percentage of the total nuclei; n = 4. e Mechanism of action of SNAIL transcription factor on myogenic differentiation of ARMS. Data on graphs are represented as mean ± SEM. *p < 0.05, n = 4.

Western blot
Protein (either nuclear and cytoplasmic fractions or total extracts) was isolated using the Nuclear Extract Kit (Active Motif, La Hulpe Belgium) according to the manufacturer’s protocol. The protein concentration was measured using the Bio-Rad Protein Assay (Bio-Rad, Hercules, California, USA) according to the manufacturer’s protocol. Western blot was performed using the anti-GAPDH rabbit mAb (14C10; Cell Signaling Technology, Leiden, The Netherlands), the anti-α-tubulin mAb (DM1A; Calbiochem, EMD Chemicals Inc San Diego, USA), the anti-histone H3 (ab1791; Abcam, Cambridge UK), the anti-SNAIL mouse mAb (L70G2; Cell Signaling), the anti-MYOD rabbit pAb (M-318; Santa Cruz, CA, USA), the anti-HDAC1 rabbit pAb (Poly6074 clone; Biolegend, San Diego CA, USA), the anti-HDAC2 mouse mAb (Biolegend, 3F3/HDAC2), anti-myogenin mouse mAb (F5D, sc-12732, Santa Cruz Biotechnology), anti-fast myosin skeletal heavy chain mouse mAb antibody (MyHC, MY-32, ab51263, Abcam), and secondary anti-rabbit and anti-mouse antibodies conjugated with horseradish peroxidase (HRP, Santa Cruz Biotechnology) as previously described.

Transcriptional activity studies
The activation of MYOD transcription factor and its binding to E-Box sequences were evaluated using isolated nuclear protein extracts from RH30 cells and TransAM® MyoD DNA-binding ELISA enzyme-linked immunosorbent assay (ELISA; Active Motif) for activated MYOD transcription factor according to the manufacturer’s protocol and using proteins from nuclear extracts. To monitor the specificity of the assay the WT consensus oligonucleotide and mutated sequences were used as competitors for MYOD binding from cell extracts.

Bioinformatic analysis
The promoter of MYF5 (~1000 bp) was screened for putative SNAIL transcription factor binding sites using a TF prediction tool called ConSite (http://consite.genereg.net)42. The results were then compared with other TF prediction tools.

Chromatin immunoprecipitation (ChIP) assay
ChIP was performed using SimpleChip Enzymatic Chromatin IP Kit (Cell Signaling Technology) according to the manufacturer’s protocol. For ChIP assays 10 μg of antibodies against SNAIL (SNAI1 E-18: sc10432X, Santa Cruz Biotechnology), 10 μg of the positive control histone H3 (D2B12 XP Rabbit mAb Chip formulated, Cell Signaling Technology) and 1 μg of the negative control IgG from the kit were used. After immunoprecipitation, the DNA was isolated using spin columns from the kit and eluted in 50 μl Elution Reagent C. PCR was performed with 2 μl of immunoprecipitated material and the products were analyzed on an 1.5% agarose gel, and visualized using a gel documentation system. The following primers were used to quantify SNAIL binding to the MYF5 promoter region 500 and 1000 bp before the translation start site and to the E-cadherin promoter (positive control for SNAIL targets).
MYF5 primer fragment 1 forward

(see figure on previous page)
5′-GCCAGCTGAAAGGGATTTCTATT-3′
5′-CACGTCCATCCTGCTAGAG-3′
5′-AAAACGTGGCTCTCCTGTTGG-3′
5′-GACCAAGGCAGTCCAACTTTT-3′
5′-TAGAGGCTACCGGCTCTAT-3′
5′-TCACAGGTGCTTTGCAGTTTC-3′

**Luciferase activity assay**

NanoLuc® luciferase plasmids variants (pNL plasmids) were ordered from Promega, WI, USA. Human genomic DNA with luciferase under control of human ubiquitin C (UBC@pNL) and MYF5 promoter (MYF5@pNL) were generated by us. Promoter fragments were cloned from human genomic DNA using primers:

- 5′-TCAGCTGAAAGGGATTTCTATT-3′
- 5′-CACGTCCATCCTGCTAGAG-3′
- 5′-AAAACGTGGCTCTCCTGTTGG-3′
- 5′-GACCAAGGCAGTCCAACTTTT-3′
- 5′-TAGAGGCTACCGGCTCTAT-3′
- 5′-TCACAGGTGCTTTGCAGTTTC-3′

**Co-immunoprecipitation**

RH30 cells were grown to confluence on 100 mm plates and nuclear extracts were prepared using the Nuclear Complex Co-IP Kit (Active Motif) according to vendor’s protocol. 100 µg of nuclear extract was used per IP reaction and incubated with either 2 µg of anti-SNAIL antibody (Sc-10432, Santa Cruz, CA, USA) or no antibody using IP Low Buffer from the kit. Protein G beads were added to each IP reaction. Following the IP, 2x Laemmli Sample Buffer was added to each IP reaction, samples were boiled and run on SDS-PAGE gel. Western blot analysis was performed using the anti-HDAC1 rabbit pAb (Poly6074 clone; Biolegend, San Diego CA, USA), the anti-HDAC2 mouse mAb (Biolegend, 3F3/HDAC2), the anti-histone H3 (ab1791; Abcam, Cambridge UK), anti-SNAIL mouse mAb (L70G2; Cell Signaling) and secondary anti-rabbit and anti-mouse antibodies conjugated with horseradish peroxidase (HRP, Santa Cruz Biotechnology) as previously described. The input RH30 nuclear extract was run as a positive control for western blot.

**Cell cycle and BrdU incorporation**

For the assessment of DNA content and BrdU incorporation, RH30 cells were differentiated for 7 days in DMEM medium with 2% HS and then they were analyzed using APC BrdU flow Kit (BD Pharmingen, CA, USA) using Attune flow cytometer (ThermoFisher Scientific), according to vendor’s protocol.

**Immunofluorescent staining**

RH30 cells or myoblasts were fixed in 4% formaldehyde (POCH) in PBS, permeabilized in 0.1% TritonX-100 (Sigma-Aldrich), blocked in 1% bovine serum albumin (BSA, Sigma-Aldrich), incubated with rabbit anti-MYF5 monoclonal antibody (ab125078, Abcam) or anti-fast myosin skeletal heavy chain antibody (MyHC, MY-32, Abcam) or anti-myosin skeletal heavy chain antibody (MyHC, MY-32, ab51263, Abcam), and then incubated with secondary goat anti-rabbit or anti-mouse antibodies conjugated with Alexa Fluor 555 (Life Technologies) and sometimes with Hoechst. The stained slides were mounted in Vectashield mounting medium with DAPI (Vector Laboratories Inc. Burlingame, CA, USA) or Dako Fluorescence Mounting Medium (Dako, Denmark). For visualization of morphology, the cells were stained with Wright’s dye (Sigma-Aldrich). Labeling was assessed by fluorescence microscopy using an Olympus BX51 or IX70 microscope (Olympus Corporation, Tokyo, Japan) and Olympus XC50 camera with cellSens Dimension software (both...
from Olympus). The images were processed using cell-Sens Dimension software or ImageJ software (National Institute of Health, USA). To quantify RH30 cells and myoblasts fusion, we calculated the fusion index by expressing the number of nuclei within MyHC-positive cells with ≥2 nuclei as a percentage of the total nuclei.

**In vivo experiments**

Animal experiments were approved by the Local Ethics Committee in Krakow in Poland. In total, 5 × 10⁶ RH30 cells were injected subcutaneously into 6- to 8-week-old NOD-SCID mice. Each experimental group contained 4 to 5 animals, and all of the experiments were repeated twice. Tumor size was evaluated using a caliper. Tumor volume was estimated using the formula \( V = D \times d^2 \times 0.5 \) (where \( V \) is the tumor volume, \( D \) is the largest dimension, and \( d \) is the smallest dimension). After 3 to 4 weeks, the mice were euthanized, and their tumors were harvested. After the evaluation of tumor weight, the tumor sections were fixed in formalin. The tumor sections were stained with hematoxylin-eosin to visualize tumor morphology using Dako EnVision Detection Systems (Dako Polska Sp. z o.o.), as previously described.

To evaluate if treatment of growing tumors with SNAIL siRNA can affect tumor growth, 5 × 10⁶ RH30 cells were injected subcutaneously into 6- to 8-week-old NOD-SCID mice. After tumors reached an average size of 60 mm³, mice were injected intratumorally with PBS, scrambled siRNA (siSCR, Silencer Select Negative Control #1 siRNA, Ambion) or siRNA against SNAIL (combination of two Silencer Select siRNA ID variants: s13185 and s13187, Ambion) at dose 3 μg/kg of body weight. Tumor growth was monitored with caliper. Three injections were performed 9, 11, and 14 days after implantation of the cells. Tumor volume was calculated as percentage of volume from the start of the therapy. Weight of tumor was analyzed 17 days after the implantation. The tumor sections were stained with hematoxylin-eosin to visualize tumor morphology using Dako EnVision Detection Systems (Dako Polska Sp. z o.o.) and after deparaffinization they were stained immunohistochemically, as described previously, with anti-SNAIL primary mouse monoclonal antibody to evaluate SNAIL expression (1:50; Santa Cruz Biotechnology; G-7: sc-271977). Each experimental group contained 3 mice.

**Statistical analysis**

Unequal stated otherwise, the results show the mean ± standard error of the mean (SEM) of at least 3 to 4 independent experiments. Statistical analysis was performed by one-way analysis of variance (ANOVA) with Tukey post-test or Student’s ́t-test using GraphPad Prism software. Differences with a ́p-value less than 0.05 were considered statistically significant. \( n \) value in figure legends describes the number of independent biological experiments.

**Acknowledgements**

We would like to acknowledge Malgorzata Sekula for transduction of RH30 cells with lentiviral vectors encoding shRNA, Grazyna Grabik for the histopathological analysis of tumors; Elżbieta Trzesniowska-Popiel for her technical assistance in immunohistochemical staining; Artur Nieszporek and Grazyna Adamek for technical help with RNA or protein isolation; Kazimierz Weglarczyk for technical help with BD FACSAria; Marta Kot for technical help with Attune Flow Cytometer. KS was a recipient of the Foundation for Polish Science’s START scholarship for outstanding young scientists and the Polish Ministry of Science and Higher Education’s scholarship for outstanding young scientists. The project was supported by the research grants from the National Science Centre in Poland to MM: 2013/09/B/NZ5/00769 and to KS: 2015/17/D/NZ5/02202.

**Author contributions**

KS designed, planned and conducted most of the experiments in vitro and in vivo, analyzed data, performed the statistical analysis and wrote the manuscript. A.K. was involved in characterization of the stable cell line RH30 shSNAIL (morphology, expression profile, tumor growth). E.T. performed Chip Assay and STR profiling. B.S. was involved in experiments with human myoblasts (qPCR analysis). T.A. and P.K. generated plasmids and viral vectors. P. K. performed bioinformatical analysis of microarray data stored in GEO database. A.U. was involved in Western blot analysis and development of CRISPR SNAIL knockout cells. B.B. measured tumor growth in vivo. M.K. was involved in designing experiments and revising the manuscript. M.M. conceived the study, designed and coordinated the study, wrote manuscript. All the authors revised the manuscript.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Supplementary Information** accompanies this paper at [https://doi.org/10.1038/s41419-018-0693-8](https://doi.org/10.1038/s41419-018-0693-8).

Received: 5 December 2017 Revised: 30 April 2018 Accepted: 10 May 2018

**References**

1. Hettmer, S. & Wagers, A. J. Muscling in: uncovering the origins of rhabdomyosarcoma. Nat. Med. 16, 171–173 (2010).
2. El Demellawy, D., McGowan-Jordan, J., de Naranjo, J., Chernetsova, E. & Nair, A. Update on molecular findings in rhabdomyosarcoma. Pathology 49, 238–246 (2017).
3. Yu, P. Y. & Guttridge, D. C. Dysregulated myogenesis in rhabdomyosarcoma. Curr. Top. Dev. Biol. 126, 285–297 (2018).
4. Szewczyk, B., Skrzypek, K. & Majka, M. Targeting MET receptor in rhabdomyosarcoma: rationale and progress. Curr. Drug Targets 18, 98–107 (2017).
5. Charytonowicz, E., Cordon-Cardo, C., Matushansky, I. & Ziman, M. Alveolar rhabdomyosarcoma: a cell of origin from a mesenchymal stem cell? Cancer Lett. 279, 126–136 (2009).
6. Asakura, A. & Rudnicki, M. A. Rhabdomyosarcomagenesis–Novel pathway found. Cancer Cell 4, 421–422 (2003).
7. Bentzinger, C. F., Wang, Y. X. & Rudnicki, M. A. Building muscle: molecular regulation of myogenesis. Cold Spring Harb. Perspect. Biol. 4, a008342 (2012).
8. Rosenberg, M. I., Georges, S. A., Asawachanchai, A., Analau, E. & Tapscott, S. J. MyoD inhibits Fstl1 and Utrn expression by inducing transcription of mir-206. J. Cell Biol. 175, 77–85 (2006).
9. Puškúllóquző, M., Lukasiewicz, E., Mekui, K., Jarocha, D. & Majka, M. Differential expression of Snail1 transcription factor and Snail2-related genes in alveolar and embryonal rhabdomyosarcoma subtypes. *Folia Histochem. Cytobiol.* **48**, 671–677 (2010).

10. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. *Nat. Rev. Mol. Cell Biol.* **3**, 155–166 (2002).

11. Peinado, H., Olmeda, D. & Cano, A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nat. Rev. Cancer* **7**, 415–428 (2007).

12. Wang, Y., Shi, J., Chai, K., Ying, X. & Zhou, B. P. The role of snail in EMT and tumorigenesis. *Curr. Cancer Drug Targets* **13**, 963–972 (2013).

13. Barrallo-Gimeno, A. & Nieto, M. A. The snail genes as inducers of cell movement and survival implications in development and cancer. *Development* **132**, 3151–3161 (2005).

14. Peinado, H., Ballestar, E., Esteller, M. & Cano, A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. *Mol. Cell. Biol.* **24**, 306–319 (2004).

15. Stanićević, J. et al. Snail-expressing fibroblasts in the tumor microenvironment display mechanical properties that support metastasis. *Cancer Res.* **75**, 284–295 (2014).

16. Rowe, R. G. et al. Mesenchymal cells reactivate Snail1 expression to drive three-dimensional invasion programs. *J. Cell Biol.* **184**, 399–408 (2009).

17. Franci, C. et al. Expression of Snail protein in tumor-stroma interface. *Oncogene* **25**, 5134–5144 (2006).

18. Soleimani, V. D. et al. Snail regulates MyoD binding-site occupancy to direct enhancer switching and differentiation-specific transcription in myogenesis. *Mol. Cell* **47**, 457–468 (2012).

19. Ignatius, M. S. et al. The NOTCH1/SNAIL1/MEF2C pathway regulates growth and self-renewal in embryonal rhabdomyosarcoma. *Cell Rep.* **19**, 2304–2318 (2017).

20. Davicioni, E. et al. Identification of a PAX3-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcoma. *Cancer Res.* **66**, 6936–6946 (2006).

21. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. Affy-analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics* **20**, 307–315 (2004).

22. Battle, R. et al. Snail controls TGF-β responsiveness and differentiation of mesenchymal stem cells. *Oncogene* **32**, 3381–3389 (2013).

23. Lin, Y. et al. Snail-dependent control of embryonic stem cell pluripotency and lineage commitment. *Nat. Commun.* **5**, 3070 (2014).

24. Skrzypek, K. et al. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression. *Oncotarget* **6**, 31378–31398 (2015).

25. Tapscott, S. J., Thayer, M. J. & Weintraub, H. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. *Science* **259**, 1450–1453 (1993).

26. Taull, R. et al. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. *Cancer Res.* **66**, 4742–4749 (2006).

27. Kim, H. K., Lee, Y. S., S vaprasad, U., Malhotra, A. & Dutta, A. Muscle-specific microRNA miR-206 promotes muscle differentiation. *J. Cell Biol.* **174**, 677–687 (2006).

28. Tenente, I. M. et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. *eLife* **6**, e19214 (2017).

29. Rudnicky, M. A. et al. MyoD or Myf-5 is required for the formation of skeletal muscle. *Cell* **75**, 1351–1359 (1993).

30. Kablar, B., Krastel, K., Tajiaksh, S. & Rudnicky, M. A. Myf5 and MyoD activation defines independent myogenic compartments during embryonic development. *Dev. Biol.* **258**, 307–318 (2003).

31. Wang, Y. X., Dumont, N. A. & Rudnicky, M. A. Muscle stem cells at a glance. *J. Cell. Sci.* **127**, 4543–4548 (2014).

32. Zibat, A. et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. *Oncogene* **29**, 6523–6530 (2010).

33. Ignatius, M. S. et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. *Cancer Cell* **21**, 680–693 (2012).

34. Buchberger, A., Freitag, D. & Arnold, H.-H. A homeo-paired domain-binding motif directs Myf5 expression in progenitor cells of limb muscle. *Development* **134**, 1171–1180 (2007).

35. Cao, L. et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. *Cancer Res.* **70**, 6497–6508 (2010).

36. Plouhinec, J.-L. et al. Pax3 and Zic1 trigger the early neural crest specification. *eLife* **5**, 1–24 (2016).

37. Wang, Y. X., Dumont, N. A. & Rudnicky, M. A. Muscle stem cells at a glance. *J. Cell Sci.* **127**, 4543–4548 (2014).

38. Skrzypek, K. et al. Interplay between heme oxygenase-1 and miR-378 affects non-small cell lung carcinoma growth, vasculatization, and metastasis. *Antioxid. Redox Sign.* **19**, 644–660 (2013).

39. Sandelin, A., Wasserman, W. W. & Lenhard, B. ConSite: web-based prediction of transcription factor binding sites. *Nucleic Acids Res.* **32**, W249–W252 (2004).